Pipeline

New data expected at lung-cancer conference on experimental drug combos

New data expected at lung-cancer conference on experimental drug combos

By

The conference will offer a glimpse at new data testing possible treatment strategies for combination therapies in the first-line setting.

Five things for pharma marketers to know: Thursday, September 3, 2015

Five things for pharma marketers to know: Thursday, September 3, 2015

By

Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six

Five things for pharma marketers to know: Wednesday, September 2

Five things for pharma marketers to know: Wednesday, September 2

By

Novartis and Amgen form neuroscience collaboration; the FDA approves a drug for people undergoing chemotherapy; a judge considers denying Pfizer's request to toss federal lawsuit

The FDA approves second PCSK9 inhibitor, Repatha

The FDA approves second PCSK9 inhibitor, Repatha

By

Amgen's Repatha will come to market priced $500 lower than the cost of Sanofi and Regeneron's Praluent.

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

By

Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.

New data sets up Jardiance  to displace DPP-4 inhibitors

New data sets up Jardiance to displace DPP-4 inhibitors

By

Eli Lilly's and BI's diabetes medication Jardiance becomes the first blood glucose-lowering drug to demonstrate it can reduce the risk of heart attack and stroke.

The FDA approves sex-drive pill, Addyi

The FDA approves sex-drive pill, Addyi

By

Sprout plans to hire 200 sales reps, targeting 30,000 doctors, to accompany the drug's launch.

Five things for pharma marketers to know: Friday, March 20

Five things for pharma marketers to know: Friday, March 20

By

A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik

GSK shingles vax shaping up to compete with Merck's

GSK shingles vax shaping up to compete with Merck's

By

The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.

Teva narrows focus, trims R&D

Teva narrows focus, trims R&D

By

The drugmaker is poised to cut 14 pipeline projects loose.

Allergan updates pipeline

Allergan updates pipeline

By

Allergan's latest pipeline news was a mix of the good and the bad. The good: a potential Lucentis competitor is progressing. The bad: migraine medication Semprana has stalled.

PhRMA uneasy about "right-to-try" laws

Colorado's version of the FDA's compassionate use rule does not sit well with lobbying group Pharmaceutical Research and Manufacturers of America.

Merck Q1 sales fall, but diabetes rises

Merck Q1 sales fall, but diabetes rises

By

Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

By

Roche also announced first-quarter sales shrank 1%.

Lilly says 2014 will not be "trough year"

Lilly says 2014 will not be "trough year"

By

Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.

Pfizer's Q4 fails to wow, but palbo' news may

Pfizer's Q4 fails to wow, but palbo' news may

By

The company said it may use Phase II data of a breast cancer drug for FDA review, part of an earnings presentation that also included its perspective on what a pre-2017 breakup would take.

The year's most popular stories

The year's most popular stories

Our year-end list captures the 10 that sparked heaviest interest.

Analyst: Don't underestimate AbbVie

Analyst: Don't underestimate AbbVie

By

Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.

Amgen PCSK9 drug passes safety test

New results from its Phase II safety trial show the LDL-cholesterol lowerer was not associated with a major increase in adverse events vs. standard of care.

Xeljanz line extension could lift drug's profile

Xeljanz line extension could lift drug's profile

By

An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.

Bayer: 5 new Phase III drugs expected in 2015

The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.

AstraZeneca reinforces oncology push

AstraZeneca reinforces oncology push

By

The drug maker is adding Amplimunne's cancer portfolio to subsidiary MedImmune's oncology efforts, one of several recent deals to add heft.

Analyst gives Merck tough love

By

Analyst Seamus Fernandez writes that Merck needs to undergo a deep overhaul, continuing the summer narrative that has enveloped Pfizer and Novartis.

Sleeper in Lilly oncology pipeline surprises Street

By

Phase III results of Eli Lilly lung cancer drug necitumumab took analysts by surprise on two levels: by helping it avoid the dustbin and in succeeding where Erbitux had failed.

Higher prices drive Lilly's second-quarter earnings

By

The Indiana drug maker logged a 6% sales increase over the same period last year. Higher prices were responsible for the majority of the growth.

Roche diabetes pipeline shrinks to two

By

A Data and Safety Monitoring Board recommendation has wiped aleglitazar from the drug maker's slate of possible diabetes medications.

FDA pushes Merck's suvorexant aside

By

The regulator says Merck needs to focus on lower doses of the drug.

Which companies stand out post-ASCO?

Which companies stand out post-ASCO?

ASCO not only offered a peek at developing treatments likely to be commercialized. Its impact also put some companies in the limelight from a business-development perspective.

Victoza in its crosshairs, Lilly primes for marketing duel

By

Eli Lilly's GLP-1 drug is still in Phase III, but recently released data suggest it could be a formidable competitor to the already marketed GLP-1 drugs, including Novo's market-leading Victoza.

J&J expands pipeline in prostate cancer

By

The pharmaceutical behemoth is betting at least $650 million on the Aragon Pharmaceuticals Ph. II drug.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.